First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-08...
First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations
About this item
Full title
Author / Creator
Wang, Xuan , Luo, Zhiguo , Chen, Jing , Chen, Yu , Ji, Dongmei , Fan, Li , Chen, Ling , Zhao, Qian , Hu, Pei , Sun, Peng , Jia, Zhongwei , Guo, Jun and Si, Lu
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
HL-085 is a selective, orally administered MEK1/2 inhibitor. We aimed to evaluate the safety and efficacy of HL-085 in patients with advanced melanoma harboring NRAS mutations.
This was a multicenter phase 1 study. HL-085 was administered twice daily in a standard 3 + 3 dose-escalation design (10 dose cohorts; 0.5-18 mg twice daily), followed by...
Alternative Titles
Full title
First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_c8dabd3a4e3f4c76bee2716e3f966d74
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_c8dabd3a4e3f4c76bee2716e3f966d74
Other Identifiers
ISSN
1741-7015
E-ISSN
1741-7015
DOI
10.1186/s12916-022-02669-7
